1st Quarter - Report

INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: SENATE; White House Office; Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Bills named: S. 3799 (117th), H.R. 6000 (117th), H.R. 5673 (117th), H.R. 6963 (117th)

Budget/Appropriations BUD

COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: HOUSE OF REPRESENTATIVES

Bills named: H.R. 7007 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.